Tap any paragraph to write a margin note. Your notes collect in the Desk below the text and file under cases with @. The side-by-side margin rail opens on a larger screen.

Code · CFR · Title 21 — Food and Drugs · Part 862 — Clinical Chemistry and Clinical Toxicology Devices · § 862.1093

§ 862.1093. Menopause test system.

284 words·~1 min read·/us/cfr/t21/s§ 862.1093·

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

(a)Identification. A menopause test system is an in vitro diagnostic device intended to measure hormones or other analytes in human clinical specimens as an aid in the determination of menopausal status in women.
(b)Classification. Class II (special controls). A menopause test system must comply with the following special controls:
(1)Design verification and validation must include the following:
(i)An appropriate traceability plan to minimize the risk of drift in the menopause test system results over time.
(ii)Detailed documentation of a clinical study to demonstrate clinical performance or, if appropriate, results from an equivalent sample set. This detailed documentation must include the following information:
(A)Results must demonstrate appropriate clinical performance relative to a well-accepted and appropriate comparator.
(B)Data must demonstrate accuracy of device output for each indicated specimen type throughout the device measuring range as appropriate for the intended use population.
(2)The labeling required under § 809.10 of this chapter must include the following:
(i)A statement in the indications for use that the device is intended to be used for the determination of menopausal status only in conjunction with other clinical and laboratory findings prior to any diagnostic or treatment decisions.
(ii)A limiting statement that the device is intended to be used for the determination of menopausal status only in conjunction with other clinical and laboratory findings prior to any diagnostic or treatment decisions.
(iii)A limiting statement appropriately describing the risks of false test results and that test results should not be relied upon in clinical decision making (e.g., to discontinue contraceptive use and/or to evaluate patients for the presence of endometrial cancer) without other clinical and laboratory findings. [90 FR 40708, Aug. 21, 2025]
Connections1 cite this
Citation graph
cites case law
§ 862.1093
Menopause test system.
Fed. Reg.×1
Cites 0Cited by 1 across 1 source
★   the supreme law of the land   ★
Don't Tread on Me
E Pluribus Unum — out of many, one

"If you don't know your rights, you don't have any."

Marginalia · a citizen's law index
A research desk, not legal advice. Always read the cited source before relying on a summary.
Questions or an issue? support@self-law.org
disclaimerMarginalia is a research index, not a law firm. Nothing on this site is legal, tax, or financial advice and no attorney–client relationship is formed by using it. Statutes, regulations, and case law change; summaries, search results, AI output, and member posts may be incomplete, out of date, or wrong. Any interpretation drawn from material on this site should be validated by a licensed attorney in your jurisdiction before you act on it.